Table 1.
Patients’ characteristics.
| All rituximab
a
N = 76 |
Rituximab for cellular analyses N = 30 |
TNFi, serology N = 82 |
|
|---|---|---|---|
| Age, median (IQR) | 60.0 (54.5–67.0) | 60.0 (54.0–67.0) | 48 (40–58) |
| Female sex, no. (%) | 64 (84) | 26 (87) | 40 (49) |
| Rituximab monotherapy, no. (%) | 18 (24) | 8 (27) | – |
|
Comedication
Methotrexate b Prednisolone c Sulfasalazine Leflunomide Plaquenil |
32 (42) 12 (16) 4 (5) 9 (12) 1 (1) |
15 (50) 1 (3) 2 (7) 3 (10) 1 (3) |
– – – – – |
| Time on rituximab treatment before D1, median years (IQR) | 6.0 (2.9–8.9) | 4.8 (2.7–9.2) | – |
| Number of rituximab infusions before D1, median (IQR) | 10.5 (4.5–16.0) | 9.0 (5.0–18.0) | – |
| Time from last rituximab infusion to vaccine or BTI, days (IQR) | |||
| Dose 2 Dose 3 Dose 4 BTI |
171 (125–214) 187 (132–226) 289 (166–369) 267 (140–432) |
150 (121–239) 180 (124–226) 284 (144–363) 212 (126–370) |
– – – – |
| Vaccine types, n (%) d | |||
|
Doses 1 and 2
mRNA-1273 BNT162b2 |
17 (22) 59 (78) |
9 (30) 21 (70) |
18 (22) 63 (78) |
|
Dose 3
mRNA-1273 BNT162b2 CBA01 |
24 (32) 49 (66) 1 (1) |
11 (37) 19 (63) 0 |
41 (51) 40 (49) 0 |
|
Dose 4
mRNA-1273 BNT162b2 CBA01 CBA45 |
32 (47) 30 (45) 3 (5) 2 (3) |
13 (48) 12 (44) 1 (4) 1 (4) |
25 (46) 27 (50) 2 (4) 0 |
| BTI the whole period, n (%) | 51 (67) | 21 (70) | 45 (55) |
| Time from last vaccine to BTI, median days (IQR) | 103 (55–169) | 100 (48–169) | 95 (45–136) |
| Number of vaccines before BTI, mean (SD) | 3.6 (0.6) | 3.7 (0.5) | – |
| BAU after the last vaccine before BTI, median (IQR) | 702 (4–2,315) | 1,483 (76–3,998) | – |
BTI, breakthrough infection; D1, vaccine dose 1; IQR, interquartile range.
a
A total of 76 were included and 30 of these also in cellular analyses.
b
Median-dose methotrexate per week: 14 mg (IQR, 10.0–20.0).
c
Median dose of prednisolone per day: 5 mg (IQR, 5.0–6.3).
d
Missing in one TNFi patient.